ImageneBio, Inc.

IMA Healthcare Biotechnology

ImageneBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $800,000.00, down 77.1% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 12.5% and free cash flow grew 23.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.04 0.01 +0.25%
Market cap
$45.7M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
3/9
Altman Z
−1.12
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
141.11 122.01 140.29 147.53
Total non-current assets
10.93 14.68 12.69 13.35
Total Assets
152.05 136.68 152.98 160.88
Total current liabilities
6.57 6.63 11.23 11.14
Total non-current liabilities
3.40 6.72 8.60 9.90
Total liabilities
9.97 13.36 19.84 21.05
Common Equity (Total)
142.07 123.33 133.14 139.83
Shareholders Equity (Total)
142.07 123.33 133.14 139.83

Show all line items

In millions of $ except per-share values · columns are period end dates